Xiaojuan Xiao

Prof. Xiaojuan Xiao

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
YZYu Zhu
Yu Zhu
ZWzi wang
zi wang
YLYanan Li
Yanan Li
Hongling PengHongling Peng
Hongling Peng
JLJing Liu
Jing Liu
XXXiaojuan Xiao
Xiaojuan Xiao
Disordered histone acetylation has emerged as a key mechanism in promoting hematological malignancies. CREB-binding protein (CREBBP) and E1A-binding protein P300 (EP300) are two key acetyltransferases and transcriptional cofactors that regulate gene expression by regulating the acetylation levels of histone proteins and non-histone proteins. CREBBP/EP300 dysregulation and CREBBP/EP300-containing complexes are critical for the initiation, progression, and chemoresistance of hematological malignancies. CREBBP/EP300 also participate in tumor immune responses by regulating the differentiation and function of multiple immune cells. Currently, CREBBP/EP300 are attractive targets for drug development and are increasingly used as favorable tools in preclinical studies of hematological malignancies. In this review, we summarize the role of CREBBP/EP300 in normal hematopoiesis and highlight the pathogenic mechanisms of CREBBP/EP300 in hematological malignancies. Moreover, the research basis and potential future therapeutic implications of related inhibitors were also discussed from several aspects. This review represents an in-depth insight into the physiological and pathological significance of CREBBP/EP300 in hematology.

1 November 2021 in Cancer Letters
Verified
Journal Article
Closed access
HYHui Yi
Hui Yi
LLLong Liang
Long Liang
HWHaiqin Wang
Haiqin Wang
SLSaiqun Luo
Saiqun Luo
LHLei Hu
Lei Hu
XXXiaojuan Xiao
Xiaojuan Xiao

14 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
WGWancheng Guo
Wancheng Guo
HWHaiqin Wang
Haiqin Wang
PCPeng Chen
Peng Chen
XSXiaokai Shen
Xiaokai Shen
BZBoxin Zhang
Boxin Zhang
XXXiaojuan Xiao
Xiaojuan Xiao
Multiple myeloma (MM) is a B-cell tumor of the blood system with high incidence and poor prognosis. With a further understanding of the pathogenesis of MM and the bone marrow microenvironment, a variety of adjuvant cell therapies and new drugs have been developed. However, the drug resistance and high relapse rate of MM have not been fundamentally resolved. Studies have shown that, in patients with MM, there is a type of poorly differentiated progenitor cell (MM stem cell-like cells, MMSCs). Although there is no recognized standard for identification and classification, it is confirmed that they are closely related to the drug resistance and relapse of MM. This article therefore systematically summarizes the latest developments in MMSCs with possible markers of MMSCs, introduces the mechanism of how MMSCs work in MM resistance and recurrence, and discusses the active pathways that related to stemness of MM.

13 March 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
HWHaiqin Wang
Haiqin Wang
YGYanfei Gong
Yanfei Gong
LLLong Liang
Long Liang
LXLing Xiao
Ling Xiao
HYHui Yi
Hui Yi
XXXiaojuan Xiao
Xiaojuan Xiao

17 March 2023 in Biomaterials
Verified
Journal Article
Closed access
XXXiaojuan Xiao
Xiaojuan Xiao
ZMZekang Ma
Zekang Ma
ZLZhenzhen Li
Zhenzhen Li
YDYiyi Deng
Yiyi Deng
YZYibin Zhang
Yibin Zhang
JLJing Liu
Jing Liu

21 April 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
LLLong Liang
Long Liang
YHYanjuan He
Yanjuan He
HWHaiqin Wang
Haiqin Wang
HZHui Zhou
Hui Zhou
LXLing Xiao
Ling Xiao
JLJing Liu
Jing Liu